These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25467130)

  • 1. Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists.
    Kenna JG; Stahl SH; Eakins JA; Foster AJ; Andersson LC; Bergare J; Billger M; Elebring M; Elmore CS; Thompson RA
    J Pharmacol Exp Ther; 2015 Feb; 352(2):281-90. PubMed ID: 25467130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
    Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS
    PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
    Hartman JC; Brouwer K; Mandagere A; Melvin L; Gorczynski R
    Can J Physiol Pharmacol; 2010 Jun; 88(6):682-91. PubMed ID: 20628435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Morgan RE; van Staden CJ; Chen Y; Kalyanaraman N; Kalanzi J; Dunn RT; Afshari CA; Hamadeh HK
    Toxicol Sci; 2013 Nov; 136(1):216-41. PubMed ID: 23956101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs.
    Thompson RA; Isin EM; Li Y; Weidolf L; Page K; Wilson I; Swallow S; Middleton B; Stahl S; Foster AJ; Dolgos H; Weaver R; Kenna JG
    Chem Res Toxicol; 2012 Aug; 25(8):1616-32. PubMed ID: 22646477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions.
    Fattinger K; Funk C; Pantze M; Weber C; Reichen J; Stieger B; Meier PJ
    Clin Pharmacol Ther; 2001 Apr; 69(4):223-31. PubMed ID: 11309550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Drug-Induced Liver Injury Prediction: Criteria Optimization of Efflux Transporter IC50 and Physicochemical Properties.
    Yucha RW; He K; Shi Q; Cai L; Nakashita Y; Xia CQ; Liao M
    Toxicol Sci; 2017 Jun; 157(2):487-499. PubMed ID: 28369588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2.
    Mano Y; Usui T; Kamimura H
    Biopharm Drug Dispos; 2007 Jan; 28(1):13-8. PubMed ID: 17061295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hepatotoxicity in patients treated with endothelin receptor antagonists: systematic review and meta-analysis of randomized clinical trials].
    Macías Saint-Gerons D; de la Fuente Honrubia C; Montero Corominas D; Catalá-López F
    Med Clin (Barc); 2014 Apr; 142(8):333-42. PubMed ID: 23540381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro model systems to investigate bile salt export pump (BSEP) activity and drug interactions: A review.
    Cheng Y; Woolf TF; Gan J; He K
    Chem Biol Interact; 2016 Aug; 255():23-30. PubMed ID: 26683212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macitentan does not interfere with hepatic bile salt transport.
    Treiber A; Äänismaa P; de Kanter R; Delahaye S; Treher M; Hess P; Sidharta P
    J Pharmacol Exp Ther; 2014 Jul; 350(1):130-43. PubMed ID: 24769543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.
    Gustafsson F; Foster AJ; Sarda S; Bridgland-Taylor MH; Kenna JG
    Toxicol Sci; 2014 Jan; 137(1):189-211. PubMed ID: 24085192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro.
    Weiss J; Herzog M; Haefeli WE
    Eur J Pharmacol; 2011 Jun; 660(2-3):298-304. PubMed ID: 21501604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the Metabolic Pathway of Bosentan and of the Cytotoxicity of Bosentan Metabolites Based on a Quantitative Modeling of Metabolism and Transport in Sandwich-Cultured Human Hepatocytes.
    Matsunaga N; Kaneko N; Staub AY; Nakanishi T; Nunoya K; Imawaka H; Tamai I
    Drug Metab Dispos; 2016 Jan; 44(1):16-27. PubMed ID: 26502773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
    Aleo MD; Luo Y; Swiss R; Bonin PD; Potter DM; Will Y
    Hepatology; 2014 Sep; 60(3):1015-22. PubMed ID: 24799086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Warner DJ; Chen H; Cantin LD; Kenna JG; Stahl S; Walker CL; Noeske T
    Drug Metab Dispos; 2012 Dec; 40(12):2332-41. PubMed ID: 22961681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Morgan RE; Trauner M; van Staden CJ; Lee PH; Ramachandran B; Eschenberg M; Afshari CA; Qualls CW; Lightfoot-Dunn R; Hamadeh HK
    Toxicol Sci; 2010 Dec; 118(2):485-500. PubMed ID: 20829430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension.
    Owen K; Cross DM; Derzi M; Horsley E; Stavros FL
    Regul Toxicol Pharmacol; 2012 Oct; 64(1):95-103. PubMed ID: 22683289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
    Dawson S; Stahl S; Paul N; Barber J; Kenna JG
    Drug Metab Dispos; 2012 Jan; 40(1):130-8. PubMed ID: 21965623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells.
    Ulvestad M; Nordell P; Asplund A; Rehnström M; Jacobsson S; Holmgren G; Davidson L; Brolén G; Edsbagge J; Björquist P; Küppers-Munther B; Andersson TB
    Biochem Pharmacol; 2013 Sep; 86(5):691-702. PubMed ID: 23856292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.